Vistagen's Fasedienol Fails to Meet Primary Endpoint in Late-Stage Social Anxiety Disorder Study
TL;DR
Vistagen's stock plummeted 79.53% after its Phase 3 trial of fasedienol for social anxiety disorder failed to meet the primary endpoint, showing no significant improvement in anxiety symptoms. The drug maintained a favorable safety profile, and the company has taken cash preservation measures to extend its runway into 2027.
Tags
Vistagen's stock is plunging 79.53% to $0.89 after the company announced that its Phase 3 study of intranasal fasedienol for social anxiety disorder did not achieve its primary endpoint. The trial failed to demonstrate a statistically significant improvement in anxiety symptoms during a simulated public speaking challenge. The favorable safety data of fasedienol were consistent with previous clinical trials. Vistagen implemented cash preservation measures to enhance operational efficiency and provide a cash runway into 2027.
